Pancreatic cancer does not respond to most immunotherapies, but RAS inhibitors could alter tumors to make them more sensitive to a novel immunotherapeutic approach. In pancreatic tumors with RAS ...
QatarEnergy CEO and Qatari minister of energy affairs, Saad al-Kaabi, said the company’s 18-million tpy Golden Pass LNG JV with ExxonMobil Corp.—which shipped its first cargo in April—is to reach full ...
The surgical robotics space has never been more competitive - with three large strategics vying for share in the soft tissue segment of the market. Medtronic recently secured regulatory clearance for ...
Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach ...
Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a phase 1/2 trial led by The University of Texas MD ...
The biotech revealed at ASCO that daraxonrasib doubled progression-free survival, a result that led a massive conference audience to rise to their feet in applause. (Darren Incorvaia) Following ...
The FDA approved daraxonrasib, the first targeted therapy for metastatic pancreatic adenocarcinoma, citing a survival benefit vs chemotherapy. The FDA approved daraxonrasib (Rasonque; Revolution ...
Lucas Kloberdanz-Dyck is a writer for Collider. He grew up creating lists, stories, and worlds, which led to his love of anime and video games. He attended Sheridan College where he earned an Honours ...
C4 Autism, a peer led neurodivergent community and career center, has officially joined The Harbor Entrepreneur Center as a resident organization. The move brings a new pipeline of trained, motivated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results